Table 2.
Open and actively recruiting trials using ATR and CHK1 inhibitors (February 2017).
| Target, Agent | Phase | Combination | Indication | NCT No. |
|---|---|---|---|---|
| ATR-VX-970, intravenous, Vertex pharmaceuticals (recently licenced to Merck KGaA, Germany) | 1 | irinotecan | Advanced solid tumours | NCT02595931 |
| 1 | Veliparib + Cisplatin | Advanced solid tumours | NCT02723864 | |
| 1/2 | Topotecan | Advanced small cell lung, cervical, endometrial, ovarian cancers | NCT02487095 | |
| 2 | Gemcitabine | Advanced ovarian/fallopian tube/primary peritoneal cancer(OC/FT/PP) | NCT02595892 | |
| 2 | Carboplatin/Gemcitabine | Advanced OC/FT/PP | NCT02627443 | |
| 2 | Cisplatin/Gemcitabine | Advanced urothelial cancers | NCT02567409 | |
| 1 | Cisplatin/Radiotherapy | Locally dvanced HPV negative SCC head and neck cancers | NCT02567422 | |
| 1 | Whole brain radiotherapy | Non- small cell lung cancers with brain mets | NCT02589522 | |
| 1 | Gemcitabine, Cisplatin, Etoposide, Carboplatin | Multiple parts including p53mut NSCLC, triple negative breast cancers | NCT02157792 | |
| ATR—AZD6738, oral, Astrazeneca | 1 | Single agent and in combination with radiotherapy | Advanced solid tumours | NCT62223923 |
| 1 | Paclitaxel | Advanced solid tumours | NCT02630199 | |
| 1 | Carboplatin, Olaparib, MEDI4736 | Advanced solid tumours | NCT02264678 | |
| CHK1—LY2606368, (Prexasertib), intravenous, Eli Lilly | 1 | Cytarabine and Fludarabine | Relapsed/Refractory Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome | NCT02649764 |
| 1 | 14C radiolabelled LY2606368 | Advanced solid tumours | NCT02778126 | |
| 1 | Single agent | Japanese patients with Advanced solid tumours | NCT02514603 | |
| 2 | Single agent | Advanced small cell lung cancer | NCT02735980 | |
| 1 | Ralimetinib (p38 MAPK inhibitor) | Advanced solid tumours | NCT02860780 | |
| 1 | Cisplatin, Cetuximab, Intensity Modulated Radiation Therapy | Advanced solid tumours, Head and Neck | NCT02555644 | |
| 1 | Cisplatin, Cetuximab, Pemetrexed, Fluorouraci | Advanced solid tumours | NCT02124148 | |
| 2 | Single agent | BRCA1/2 Mutation Associated Breast or Ovarian Cancer, Triple Negative Breast Cancer, High Grade Serous OC, and Metastatic CRPC | NCT02203513 | |
| 2 | Single agent | Advanced Solid Tumours Exhibiting Replicative Stress or Homologous Recombination Repair Deficiency | NCT02873975 | |
| CHK1—SRA 737 previously known CCT245737, Sierra Oncology Inc. | 1 | Gemcitabine + Cisplatin or Gemcitabine Alone | Advanced solid tumours | NCT02797977 |
| 1 | Single agent | Advanced solid tumours | NCT02797964 |